RU2749834C2 - Кфтр регуляторы и способы их применения - Google Patents

Кфтр регуляторы и способы их применения Download PDF

Info

Publication number
RU2749834C2
RU2749834C2 RU2018126958A RU2018126958A RU2749834C2 RU 2749834 C2 RU2749834 C2 RU 2749834C2 RU 2018126958 A RU2018126958 A RU 2018126958A RU 2018126958 A RU2018126958 A RU 2018126958A RU 2749834 C2 RU2749834 C2 RU 2749834C2
Authority
RU
Russia
Prior art keywords
substituted
unsubstituted
nhc
hydrogen
alkyl
Prior art date
Application number
RU2018126958A
Other languages
English (en)
Russian (ru)
Other versions
RU2018126958A3 (OSRAM
RU2018126958A (ru
Inventor
Алан Веркмэн
Марк Х. ЛЕВИН
Онур СИЛ
Судзин ЛИ
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа
Publication of RU2018126958A publication Critical patent/RU2018126958A/ru
Publication of RU2018126958A3 publication Critical patent/RU2018126958A3/ru
Application granted granted Critical
Publication of RU2749834C2 publication Critical patent/RU2749834C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
RU2018126958A 2015-12-24 2016-12-23 Кфтр регуляторы и способы их применения RU2749834C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387590P 2015-12-24 2015-12-24
US62/387,590 2015-12-24
PCT/US2016/068569 WO2017112951A1 (en) 2015-12-24 2016-12-23 Cftr regulators and methods of use thereof

Publications (3)

Publication Number Publication Date
RU2018126958A RU2018126958A (ru) 2020-01-27
RU2018126958A3 RU2018126958A3 (OSRAM) 2020-03-10
RU2749834C2 true RU2749834C2 (ru) 2021-06-17

Family

ID=59091271

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018126958A RU2749834C2 (ru) 2015-12-24 2016-12-23 Кфтр регуляторы и способы их применения

Country Status (18)

Country Link
US (6) US10604492B2 (OSRAM)
EP (2) EP4019501B1 (OSRAM)
JP (2) JP6938510B2 (OSRAM)
KR (1) KR102733897B1 (OSRAM)
CN (2) CN108848668B (OSRAM)
AU (1) AU2016379444B2 (OSRAM)
BR (1) BR112018012949B1 (OSRAM)
CL (1) CL2018001715A1 (OSRAM)
CO (1) CO2018007237A2 (OSRAM)
DK (1) DK3394040T3 (OSRAM)
ES (2) ES3066112T3 (OSRAM)
IL (1) IL260208B2 (OSRAM)
MX (2) MX383072B (OSRAM)
PL (1) PL3394040T3 (OSRAM)
PT (1) PT3394040T (OSRAM)
RU (1) RU2749834C2 (OSRAM)
WO (1) WO2017112951A1 (OSRAM)
ZA (1) ZA201804230B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3066112T3 (en) * 2015-12-24 2026-05-11 The Regents Of The Univ Of California Cftr regulators and methods of use thereof
EP3672598A4 (en) * 2017-08-24 2021-04-28 The Regents of The University of California OCULAR PHARMACEUTICAL COMPOSITIONS
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
TWI845795B (zh) * 2019-12-05 2024-06-21 美商汎達製藥公司 眼用醫藥組合物
IL300628A (en) 2020-09-10 2023-04-01 Vanda Pharmaceuticals Inc Methods for the treatment of cyclic diseases or conditions-PDE IV
WO2025179141A1 (en) 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047897A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
WO2004031184A1 (en) * 2002-10-01 2004-04-15 Johnson & Johnson Pharmaceutical Research & Development, Inc. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
EA004540B1 (ru) * 1998-03-27 2004-06-24 Янссен Фармацевтика Н.В. Тризамещенные производные 1,3,5-триазина для лечения вич-инфекционных заболеваний
WO2005103015A1 (en) * 2004-03-24 2005-11-03 Reddy Us Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
EA009728B1 (ru) * 2001-09-21 2008-02-28 Редди Ю-Эс Терапьютикс, Инк. Триазиновые соединения и их применение в медицине
WO2009091388A2 (en) * 2007-12-21 2009-07-23 Progenics Pharmaceuticals, Inc. Triazines and related compounds having antiviral activity, compositions and methods thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK35124C (da) 1924-03-19 1925-10-12 Niels Christian Carl S Nielsen Anordning ved Ægisolatorer og lignende.
DK72517C (da) 1948-04-08 1951-05-15 Hans Dr Ing Wolf Kobling til paralleldrift af vekselstrømsmotorer.
DK101373C (da) 1962-03-16 1965-03-29 Hoechst Ag Fremgangsmåde til fremstilling af vandopløselige monoazofarvestoffer.
ZA794209B (en) 1978-08-15 1980-07-30 Fisons Ltd Pharmaceutically active heterocyclic compounds
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS62126178A (ja) * 1985-11-26 1987-06-08 Mitsubishi Petrochem Co Ltd 新規トリアジン誘導体及びこれを含む除草剤
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1994011355A1 (fr) 1992-11-19 1994-05-26 Dainippon Pharmaceutical Co., Ltd. Derive de 3,4-dihydro-1(2-hydroxyphenyl)-2(1h)-quinoxalinone et compose associe
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6403598B1 (en) 1998-01-30 2002-06-11 R-Tech Ueno, Ltd. Ophthalmic composition
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
AU1917999A (en) 1998-03-31 1999-10-18 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
US7163943B2 (en) * 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US20070161637A1 (en) * 2003-07-22 2007-07-12 Neurogen Corporation Substituted pyridin-2-ylamine analogues
WO2005075435A1 (en) 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
JP2008538107A (ja) * 2005-03-18 2008-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変異型ｃｆｔｒプロセシングの修正において活性を有する化合物及びその用途
WO2007095812A1 (en) 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
WO2008006050A2 (en) * 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
PL2149560T3 (pl) 2007-05-22 2015-10-30 Astellas Pharma Inc 1-podstawiony związek tetrahydroizochinolinowy
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
AU2009221327B2 (en) 2008-03-05 2014-03-27 Merck Patent Gmbh Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
KR101727762B1 (ko) * 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
FR2958645B1 (fr) 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
CN105130948A (zh) * 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
WO2014097147A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
JP6425724B2 (ja) 2013-08-08 2018-11-21 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Ｃｆｔｒモジュレーターとしてのチエノ［２，３−ｃ］ピラン
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US10354851B2 (en) 2015-09-11 2019-07-16 Iontof Technologies Gmbh Secondary ion mass spectrometer and secondary ion mass spectrometric method
RU2730855C2 (ru) 2015-12-24 2020-08-26 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
ES2901002T3 (es) 2015-12-24 2022-03-21 Univ California Derivados de N-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-bencenoacetamida y compuestos relacionados como activadores de CFTR para tratar estreñimiento o colestasis
ES3066112T3 (en) 2015-12-24 2026-05-11 The Regents Of The Univ Of California Cftr regulators and methods of use thereof
MY195904A (en) 2015-12-24 2023-02-27 Respivert Ltd Indolinones Compounds and Their use in the Treatment Of Fibrotic Diseases
EP3672598A4 (en) 2017-08-24 2021-04-28 The Regents of The University of California OCULAR PHARMACEUTICAL COMPOSITIONS
JP7256631B2 (ja) 2018-11-01 2023-04-12 株式会社豊田中央研究所 距離測定装置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004540B1 (ru) * 1998-03-27 2004-06-24 Янссен Фармацевтика Н.В. Тризамещенные производные 1,3,5-триазина для лечения вич-инфекционных заболеваний
WO2001047897A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
EA009728B1 (ru) * 2001-09-21 2008-02-28 Редди Ю-Эс Терапьютикс, Инк. Триазиновые соединения и их применение в медицине
WO2004031184A1 (en) * 2002-10-01 2004-04-15 Johnson & Johnson Pharmaceutical Research & Development, Inc. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
WO2005103015A1 (en) * 2004-03-24 2005-11-03 Reddy Us Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
WO2009091388A2 (en) * 2007-12-21 2009-07-23 Progenics Pharmaceuticals, Inc. Triazines and related compounds having antiviral activity, compositions and methods thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
D. W. Ludovici et al. "Evolution of Anti-HIV Drug Candidates Part 2: Diaryltriazine (DATA) Analogues" Bioorganic & Medicinal Chemistry Letters, 11, 2001, 2229-2234. *
J. R. Dudley et al. "Cyanuric Chloride Derivatives. III. Alkoxy-s-triazines" Journal of the American Chemical Society, vol.73, 1951, 2986-2990. *
L. Somogyi et al. "Cyclisierungsreaktionen von mono- und disubstituierten Biguaniden mit Phenylisothiocyanat" Chemische Berichte, 100(6), 1967, 1975-1982. *
M. H. Shah et al. "Synthesis and Diuretic Activity of 2-Amino-4-arylamino-6-mercapto-s-triazines and Related Derivatives" 1968, 1167-1171. *
N. Baindur et al. "2-Hydroxy-4,6-diamino-[1,3,5]triazines: A Novel Class of VEGF-R2 (KDR) Tyrosine Kinase Inhibitors" Journal of Medicinal Chemistry, vol. 48, N6, 2005, 1717-1720. *
O. Moran et al. "Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains" CMLS Cellular and Molecular Life Sciences, 62, 2005, 446-460. *
T. Ma et al. "High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening" The Journal of Biological Chemistry, vol. 277, N 40, 2002, 37235-37241. *
T. Ma et al. "High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening" The Journal of Biological Chemistry, vol. 277, N 40, 2002, 37235-37241. O. Moran et al. "Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains" CMLS Cellular and Molecular Life Sciences, 62, 2005, 446-460. J. R. Dudley et al. "Cyanuric Chloride Derivatives. III. Alkoxy-s-triazines" Journal of the American Chemical Society, vol.73, 1951, 2986-2990. L. Somogyi et al. "Cyclisierungsreaktionen von mono- und disubstituierten Biguaniden mit Phenylisothiocyanat" Chemische Berichte, 100(6), 1967, 1975-1982. M. H. Shah et al. "Synthesis and Diuretic Activity of 2-Amino-4-arylamino-6-mercapto-s-triazines and Related Derivatives" 1968, 1167-1171. В. В. Довлатян и др. "Синтез и термическое разложение галогеналкокси-(тио)-симм-триазинов" Армянский химический журнал, т.41, N *
Z. Li et al. "Revealing Interaction Mode Between HIV-1 Reverse Transcriptase and Diaryltriazine Analog Inhibitor" Chemical Biology & Drug Desing, 72, 2008, 350-359. *
Z. Li et al. "Revealing Interaction Mode Between HIV-1 Reverse Transcriptase and Diaryltriazine Analog Inhibitor" Chemical Biology & Drug Desing, 72, 2008, 350-359. EA 009728 B1 (РЕДДИ-Ю-ЭС ТЕРАПЬЮТИКСБ ИНК.) 28.02.2008. *
В. В. Довлатян и др. "Синтез и термическое разложение галогеналкокси-(тио)-симм-триазинов" Армянский химический журнал, т.41, N6, 1988, 346-351. *

Also Published As

Publication number Publication date
PL3394040T3 (pl) 2022-05-02
US11230535B2 (en) 2022-01-25
KR102733897B1 (ko) 2024-11-22
US12391654B2 (en) 2025-08-19
ZA201804230B (en) 2020-11-25
RU2018126958A3 (OSRAM) 2020-03-10
WO2017112951A1 (en) 2017-06-29
JP2019505502A (ja) 2019-02-28
IL260208B1 (en) 2023-12-01
AU2016379444A1 (en) 2018-07-12
US20180327369A1 (en) 2018-11-15
BR112018012949A2 (pt) 2018-12-11
JP7297827B2 (ja) 2023-06-26
US10604492B2 (en) 2020-03-31
EP4019501B1 (en) 2026-02-04
MX383072B (es) 2025-03-13
EP3394040A1 (en) 2018-10-31
DK3394040T3 (da) 2022-03-28
KR20180102590A (ko) 2018-09-17
BR112018012949B1 (pt) 2023-11-14
CN108848668A (zh) 2018-11-20
US20250109113A1 (en) 2025-04-03
CN115710233A (zh) 2023-02-24
IL260208A (en) 2018-07-31
ES2909316T3 (es) 2022-05-06
CO2018007237A2 (es) 2018-07-19
US20230357170A1 (en) 2023-11-09
NZ743726A (en) 2025-02-28
CL2018001715A1 (es) 2018-10-26
US20200181097A1 (en) 2020-06-11
EP3394040A4 (en) 2019-08-07
US12065412B2 (en) 2024-08-20
EP4019501A1 (en) 2022-06-29
CA3009510A1 (en) 2017-06-29
ES3066112T3 (en) 2026-05-11
PT3394040T (pt) 2022-03-24
EP3394040B1 (en) 2021-12-22
AU2016379444B2 (en) 2021-04-29
RU2018126958A (ru) 2020-01-27
MX2021006439A (es) 2021-07-02
IL260208B2 (en) 2024-04-01
US20220081402A1 (en) 2022-03-17
JP6938510B2 (ja) 2021-09-22
US20260103446A1 (en) 2026-04-16
JP2021185183A (ja) 2021-12-09
CN108848668B (zh) 2022-04-26

Similar Documents

Publication Publication Date Title
RU2742934C2 (ru) Кфтр регуляторы и способы их применения
US12065412B2 (en) CFTR regulators and methods of use thereof
RU2730855C2 (ru) Кфтр регуляторы и способы их применения